To the Editor We read with interest the article by Hornberger and Siegel,1 which suggested that the pigmented lesion assay (PLA)2 may reduce costs and improve the care of patients with skin lesions suspicious for melanoma. The noninvasive sampling of RNA is a promising approach for the diagnosis of melanoma, especially considering the intrinsic limitations of visual inspection and the cost and morbidity of histologic evaluation. It is important that we continue to develop and test instruments, such as the PLA, that have potential to decrease unnecessary biopsies of benign pigmented skin lesions.
Beatson M, Weinstock MA. Further Consideration of the Pigmented Lesion Assay. JAMA Dermatol. 2019;155(3):393. doi:10.1001/jamadermatol.2018.5478
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: